News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Big Pharma Spending $240B to Replace Blockbusters Before Patents Expire
Patent cliffs are forcing pharmaceutical giants into a bidding war for biotech assets. M&A hit $240 billion last year as companies like Merck and Pfizer race to plug revenue gaps from expiring drugs.
Brain Reference Map From 54K Scans Shows White Matter Changes Across Life
USC researchers built lifespan charts for brain neural pathways using diffusion MRI data from 54,583 people. The tool detects disease patterns in dementia, schizophrenia risk, and genetic conditions—and it's publicly available.
Fulcrum kills sickle cell drug after FDA cites cancer risk from rival therapy
Fulcrum Therapeutics halted pociredir development following FDA concerns about secondary blood cancers observed with Ipsen's Tazverik. The decision wipes out $1.5B in projected peak sales and triggers a 51% stock drop.
Measles vaccine T cells cross-react to deadly Nipah virus in first study
Scientists at La Jolla Institute found that immune cells primed by MMR vaccination can recognize Nipah virus, suggesting a path to broad paramyxovirus vaccines. Here's what the data shows and what happens next.
Spatial Imaging Reveals Why Antibodies Fail Inside Solid Tumors
A platform from Vanderbilt and Stanford visualizes drug delivery barriers in human tumors, showing stromal tissue blocks antibody penetration. Here's what oncology teams should know.
Lilly bets $1.9B on Ascidian's RNA exon editors for kidney disease
Eli Lilly will pay Boston biotech Ascidian up to $1.9 billion to develop RNA exon editors targeting inherited kidney diseases. The deal covers discovery, preclinical work, and commercialization rights.
Alzheimer's drug makers shift focus from amyloid to inflammation and tau
As amyloid-targeting drugs lose momentum, biotech pipelines are expanding around inflammation, tau proteins, and biomarker screening. What this means for treatment timelines.
NASA's ISS closing—private companies race to fill the drug research gap
NASA is decommissioning the International Space Station. Drug makers and startups are already betting on private alternatives to continue microgravity R&D. Here's what's at stake.
Goa's obesity rate hits 45%, blood sugar crisis tops nation
Nearly half of Goa's population is now overweight or obese, with 32.1% of men showing elevated blood sugar—the highest in India. New health survey data reveals how fast the state's lifestyle disease burden is rising.
India plans 75,000 new medical seats in 5 years as screening reaches 36 crore
Union health minister JP Nadda announced 75,000 additional undergraduate and postgraduate medical seats over the next five years, with 23,000 already added. India has screened 36 crore people for oral cancer and expanded AIIMS to 23 institutions.
India's Medical Regulator Orders Hospitals to Stop Reusing Needles
The National Medical Commission has directed all medical colleges to use single-use sterile needles only, citing preventable HIV and hepatitis outbreaks from unsafe injection practices across India's millions of daily procedures.
Physical therapists can't fill demand. Agentic AI is closing the gap.
Demand for physical therapy outpaces clinician supply, leaving patients in long waits. Agentic AI can triage patients, deliver hybrid care, and reduce overall system burden — here's why hospitals should adopt it now.